Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome

Author(s): Rosaria V. Giglio, Anca P Stoian, Angelo M. Patti*, Ali A. Rizvi, Vasily Sukhorukov, Marcello Ciaccio, Alexander Orekhov, Manfredi Rizzo

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 35 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Metabolic syndrome is a clinical condition that deserves special attention because it puts the individual at high cardiovascular risk, especially heart attack and stroke. Considering precision medicine, it would be advisable to evaluate the individual cardio-metabolic risk by estimating the coexistence of risk factors (abdominal obesity, low level of High-Density Lipoprotein Cholesterol, High Triglycerides, and small dense Low-Density Lipoproteins sub-classes, hypertension, and elevated fasting glycemia), which could engrave on metabolism increasing cardiovascular mortality.

Objective: To identify genetic and epigenetic biomarkers may assist in the possibility of helping follow-up strategies and other measures of prevention and in metabolic risk.

Methods: We searched for studies that valued the combination between epigenetic biomarkers and all factors of cardio-metabolic risk.

Results: Numerous researches have investigated the molecular start of metabolic alterations, focusing on the epigenetic mark, as methylation of DNA, histone modifications and non.coding RNAs. It has been found that DNA methylation is the most searched epigenetic sign in the human genome concerning the control of gene expression.

Conclusion: For the screening, diagnosis, and prognosis of metabolic syndrome and the prescription of personalized medicine, the DNA methylation biomarkers specify for subjects have been recognized as an ensuring tool. While these results are promising, further investigations are needed to unravel the complicated synergic association of the genome, epigenome and the situations related to metabolic pathology.

Keywords: Metabolic syndrome, inflammation, genetic, epigenetic, metabolic pathways, biomarkers, management.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 35
Year: 2021
Page: [3729 - 3740]
Pages: 12
DOI: 10.2174/1381612827666210412145915
Price: $95

Article Metrics

PDF: 115